Sugi Predict

Sugi Predict / Compounds / SCHEMBL25323925

SCHEMBL25323925

SCHEMBL25323925

O=C(NC1CC1)c1ccc(N2CCNCC2)c(F)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 4/20 0.52
▸ HSD11B1 P28845 2/20 0.43
▸ PRKAA2 P54646 1/20 0.42
▸ BACE1 P56817 1/20 0.42
▸ HPGDS O60760 1/20 0.41
▸ BMPR1B O00238 1/20 0.41
▸ BMPR1A P36894 1/20 0.41
▸ TGFBR1 P36897 1/20 0.41
▸ ACVRL1 P37023 1/20 0.41
▸ ACVR1 Q04771 1/20 0.41
▸ ACKR3 P25106 1/20 0.40
▸ SMYD3 Q9H7B4 3/20 0.40
▸ HTR6 P50406 1/20 0.40
▸ HDAC3 O15379 1/20 0.39
▸ HDAC1 Q13547 1/20 0.39
▸ HDAC2 Q92769 1/20 0.39
▸ TP53 P04637 1/20 0.39
▸ PARP2 Q9UGN5 1/20 0.38
▸ CHEK1 O14757 1/20 0.38
▸ CD38 P28907 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL25320690 0.99 PARP1 (0.51) PARP1HSD11B1PRKAA2BACE1HPGDS
SCHEMBL31514765 0.89 PARP1 (0.43) PARP1HSD11B1BACE1HPGDSACKR3
Hydrochloric Acid SCHEMBL31552827 0.87 PARP1 (0.44) PARP1BACE1HPGDSHDAC3HDAC1
SCHEMBL31424664 0.85 BACE1 (0.41) PARP1PRKAA2BACE1HTR6HDAC3
SCHEMBL31465737 0.85 PARP1 (0.45) PARP1BACE1PARP2CD38
SCHEMBL25235207 0.85 PARP1 (0.45) PARP1HSD11B1HPGDSSMYD3HDAC3
SCHEMBL30273150 0.85 PARP1 (0.45) PARP1HSD11B1HPGDSSMYD3HDAC3
SCHEMBL31465719 0.85 HSD11B1 (0.43) PARP1HSD11B1PRKAA2BACE1HPGDS
Hydrochloric Acid SCHEMBL31552839 0.84 PARP1 (0.44) PARP1HSD11B1HPGDSSMYD3HDAC3
Hydrochloric Acid SCHEMBL31552854 0.84 SMYD3 (0.43) PARP1HSD11B1PRKAA2BACE1HPGDS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260098024-A1 PARP1 INHIBITORS AND USES THEREOF XINTHERA INC (US) 2026-04-09 — — US disclosed
US-20250215013-A1 SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF IMPACT THERAPEUTICS (SHANGHAI), INC. (CN) 2025-07-03 — — US disclosed
US-20250171418-A1 PARP1 INHIBITORS AND USES THEREOF XINTHERA, INC. 2025-05-29 — — US disclosed
WO-2025092905-A1 PARP INHIBITORS AND USES THEREOF SUZHOU EOC MEDICAL RESEARCH CO., LTD. (CN) 2025-05-08 — — WO disclosed
WO-2025091346-A1 PARP INHIBITORS AND USES THEREOF SUZHOU EOC MEDICAL RESEARCH CO., LTD. (CN) 2025-05-08 — — WO disclosed
CN-119431314-A Substituted nitrogen-containing bicyclic compounds and uses thereof 广东东阳光药业股份有限公司 2025-02-14 — — CN disclosed
EP-4490161-A1 SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF Impact Therapeutics (Shanghai), Inc. (CN) 2025-01-15 — — EP disclosed
EP-4469449-A1 PARP1 INHIBITORS AND USES THEREOF Xinthera, Inc. (US) 2024-12-04 — — EP disclosed
CN-119013279-A Substituted tricyclic compounds as PARP inhibitors and uses thereof 上海瑛派药业有限公司 2024-11-22 — — CN disclosed
EP-4460497-A1 PARP1 INHIBITORS AND USES THEREOF Xinthera, Inc. (US) 2024-11-13 — — EP disclosed
CN-118574824-A PARP1 inhibitors and uses thereof 新特拉有限公司 2024-08-30 — — CN disclosed
CN-118510767-A PARP1 inhibitors and uses thereof 新特拉有限公司 2024-08-16 — — CN disclosed
EP-4392425-A1 SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND USE THEREOF Impact Therapeutics (Shanghai), Inc. (CN) 2024-07-03 — — EP disclosed
CN-117980307-A Substituted tricyclic compounds as PARP inhibitors and application thereof 上海瑛派药业有限公司 2024-05-03 — — CN disclosed
WO-2023169226-A1 SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF Impact Therapeutics (Shanghai), Inc (CN) 2023-09-14 — — WO disclosed
WO-2023146960-A1 PARP1 INHIBITORS AND USES THEREOF XINTHERA, INC. (US) 2023-08-03 — — WO disclosed
WO-2023146960-A1 PARP1 INHIBITORS AND USES THEREOF XINTHERA, INC. (US) 2023-08-03 — — WO disclosed
WO-2023146957-A1 PARP1 INHIBITORS AND USES THEREOF XINTHERA, INC. (US) 2023-08-03 — — WO disclosed
WO-2023146957-A1 PARP1 INHIBITORS AND USES THEREOF XINTHERA, INC. (US) 2023-08-03 — — WO disclosed
WO-2023025307-A1 SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND USE THEREOF IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) 2023-03-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250215013-A1 SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF PARP1, PARP2, PARP3 PARP1 1/4885HSD11B1 2195/4885PRKAA2 375/4885
US-20260098024-A1 PARP1 INHIBITORS AND USES THEREOF PARP1, PARP11, PARP16 PARP1 1/4885HSD11B1 783/4885PRKAA2 366/4885
US-20250171418-A1 PARP1 INHIBITORS AND USES THEREOF PARP1, PARP11, PARP12 PARP1 1/4885HSD11B1 3307/4885PRKAA2 152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.